Twist Bioscience Corporation $TWST Stock: Sumitomo Mitsui Trust Group Inc. Decreases Holdings

Posted by Brian Himes on Nov 2nd, 2026

Sumitomo Mitsui Trust Group Inc. trimmed its holdings in Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 22.4% during the 3rd quarter, Holdings Channel.com reports. The firm owned 776,099 shares of the company’s stock after selling 224,245 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Twist Bioscience were worth $149,973,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Twist Bioscience during the 3rd quarter valued at about $5,712,000. ProShare Advisors LLC boosted its stake in shares of Twist Bioscience by 4.3% in the third quarter. ProShare Advisors LLC now owns 10,615 shares of the company’s stock worth $2,051,000 after buying an additional 441 shares during the last quarter. Vise Technologies Inc. acquired a new stake in Twist Bioscience during the third quarter worth about $372,000. State of Wyoming grew its holdings in Twist Bioscience by 25.3% during the third quarter. State of Wyoming now owns 2,242 shares of the company’s stock worth $433,000 after acquiring an additional 452 shares during the period. Finally, Choreo LLC raised its position in Twist Bioscience by 6.9% during the third quarter. Choreo LLC now owns 7,452 shares of the company’s stock valued at $1,440,000 after acquiring an additional 483 shares in the last quarter.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $152.78 on Monday. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $219.71. The business’s fifty day simple moving average is $153.11 and its 200-day simple moving average is $88.83. The firm has a market cap of $9.58 billion, a PE ratio of -68.82 and a beta of 2.25. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The business had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.33 earnings per share. Equities analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 2,462 shares of the company’s stock in a transaction dated Friday, October 9th. The shares were sold at an average price of $156.30, for a total value of $384,810.60. Following the transaction, the chief financial officer owned 98,114 shares of the company’s stock, valued at $15,335,218.20. This represents a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of the stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,905,421.44. Following the transaction, the senior vice president directly owned 106,632 shares of the company’s stock, valued at approximately $20,140,652.16. This trade represents a 8.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 601,920 shares of company stock worth $93,768,202 in the last 90 days. Insiders own 3.08% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. UBS Group initiated coverage on Twist Bioscience in a report on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 price target for the company. BWS Financial restated a “sell” rating and issued a $45.00 target price on shares of Twist Bioscience in a report on Friday, September 18th. Canaccord Genuity Group raised their target price on Twist Bioscience from $120.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Piper Sandler raised their target price on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 5th. Finally, Robert W. Baird lifted their price target on Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $143.67.

Check Out Our Latest Analysis on TWST

Twist Bioscience Company Profile

(Free Report)

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.